US 12,140,468 B2
Method for dosing a target component
Syed Muhammad Mushahid Azher, Weil am Rhein (DE); Christian Gebauer, Kandern (DE); Christian Karl Paasche, Bad Säckingen (DE); Marc Michaelis, Lörrach (DE); and Isabelle Hemming, Schopfheim (DE)
Assigned to Hüttlin GmbH, Schopfheim (DE)
Appl. No. 17/613,235
Filed by Hüttlin GmbH, Schopfheim (DE)
PCT Filed Sep. 9, 2020, PCT No. PCT/EP2020/075135
§ 371(c)(1), (2) Date Nov. 22, 2021,
PCT Pub. No. WO2021/052824, PCT Pub. Date Mar. 25, 2021.
Claims priority of application No. 10 2019 214 156.0 (DE), filed on Sep. 17, 2019.
Prior Publication US 2022/0214207 A1, Jul. 7, 2022
Int. Cl. G01G 13/24 (2006.01); B01F 33/84 (2022.01); B01F 35/88 (2022.01)
CPC G01G 13/241 (2013.01) [B01F 33/84 (2022.01); B01F 35/881 (2022.01)] 15 Claims
OG exemplary drawing
 
1. A method for dosing a target component (20), the method comprising:
dosing the target component (20), using a dosing system (10), to a target value (Z20) that corresponds to a desired nominal value (S20soll),
thereafter, calculating a target value (Z21) of at least one further component (21, 22, 23) for after-dosing that is lower than a desired nominal value (S21soll) of the at least one further component (21, 22, 23) for after-dosing,
thereafter, dosing the at least one further component (21, 22, 23) for after-dosing to the target value (Z21) of the at least one further component (21, 22, 23) for after-dosing,
thereafter, determining an actual value (G20ist) of the target component (20) and at least one actual value (G21ist) of the at least one further component (21, 22, 23) for after-dosing,
thereafter, calculating a content (A) of the target component (20) based on the actual value (G20ist) of the target component (20) and/or the actual value (G21ist) of the at least one further component (21, 22, 23) for after-dosing,
thereafter, comparing the content (A) to a limit value (T) or to a tolerance band (T),
thereafter, determining that the limit value (T) or the tolerance band (T) is exceeded, and
thereafter, again dosing the at least one further component (21, 22, 23) for after-dosing.